<--- Back to Details
First PageDocument Content
Cyclopropanes / Non-nucleoside reverse transcriptase inhibitors / Antiretroviral drug / Abacavir / Reverse-transcriptase inhibitor / Nevirapine / Efavirenz / Patent / Raltegravir / Chemistry / Organic chemistry / Organofluorides
Date: 2015-04-20 05:17:21
Cyclopropanes
Non-nucleoside reverse transcriptase inhibitors
Antiretroviral drug
Abacavir
Reverse-transcriptase inhibitor
Nevirapine
Efavirenz
Patent
Raltegravir
Chemistry
Organic chemistry
Organofluorides

ANTIRETROVIRAL PRIORITIES OF THE MEDICINES PATENT POOL

Add to Reading List

Source URL: www.medicinespatentpool.org

Download Document from Source Website

File Size: 338,44 KB

Share Document on Facebook

Similar Documents

Switching between raltegravir resistance pathways analyzed by deep sequencing Rithun Mukherjeea, Shane T. Jensenb, Frances Malea, Kyle Bittingera, Richard L. Hodinkac,d, Michael D. Millere and Frederic D. Bushmana Object

DocID: 1rImN - View Document

Clinical medicine / Breakthrough therapy / Medicine / Antineoplastic drugs / Pharmacology / Monoclonal antibodies / Bristol-Myers Squibb / Nivolumab / Melanoma / Programmed cell death protein 1 / Pembrolizumab / Raltegravir

12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO Box

DocID: 1qIwe - View Document

Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (avrilANRS 160 RalFE Evaluation des propriétés pharmacocinétiques et de la tolérance du raltégravir pendant l

DocID: 1lV9R - View Document

Cyclopropanes / Non-nucleoside reverse transcriptase inhibitors / Antiretroviral drug / Abacavir / Reverse-transcriptase inhibitor / Nevirapine / Efavirenz / Patent / Raltegravir / Chemistry / Organic chemistry / Organofluorides

ANTIRETROVIRAL PRIORITIES OF THE MEDICINES PATENT POOL

DocID: 1fNy0 - View Document

Merck Sharp Dohme Haarlem raltegravir Isentress HIV aanbiedingsbrief rapporten ministerPOVOOPEN.DOC

DocID: 1ey1D - View Document